Pseudomonas aeruginosa infection in cystic fibrosis: Prevent, eradicate or both?

Thorax

Volumn 65, Issue 10, 2010, Pages 849-851

  Eber, Ernst ^a   Zach, Maximilian S ^a  

^a Universitatsklinik fur Kinder und Jugendheilkunde Graz   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; COLISTIN; MANNITOL; PLACEBO; TOBRAMYCIN;

AGE DISTRIBUTION; ANTIBIOTIC PROPHYLAXIS; BACTERIAL STRAIN; BRONCHUS DISEASE; CLINICAL TRIAL; COUGHING; EDITORIAL; ERADICATION THERAPY; HAEMOPHILUS; HUMAN; LUNG FIBROSIS; PRIORITY JOURNAL; PROGNOSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; STAPHYLOCOCCUS AUREUS;

EID: 77957205095     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2010.138891     Document Type: Editorial

References (43)

1. Armstrong DS, Grimwood K, Carzino R, et al. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 1995;310:1571-2.
2. Khan TZ, Wagener JS, Bost T, et al. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995;151:1075-82.
3. Ranganathan SC, Bush A, Dezateux C, et al; The London Collaborative Cystic Fibrosis Group. Relative ability of full and partial forced expiratory maneuvers to identify diminished airway function in infants with cystic fibrosis. Am J Respir Crit Care Med 2002;166:1350-7.
4. Long FR, Williams RS, Castile RG. Structural airway abnormalities in infants and young children with cystic fibrosis. J Pediatr 2004;144:154-61.
5. Linnane BM, Hall GL, Nolan G, et al; on behalf of the Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST-CF). Lung function in infants with cystic fibrosis diagnosed by newborn screening. Am J Respir Crit Care Med 2008;178:1238-44.
6. Sly PD, Brennan S, Gangell C, et al; on behalf of the Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST-CF). Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med 2009;180:146-52.
7. Armstrong DS, Grimwood K, Carlin JB, et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997;156:1197-204.
8. Dakin CJ, Numa AH, Wang H, et al. Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 2002;165:904-10.
9. Sagel SD, Gibson RL, Emerson J, et al; For the Inhaled Tobramycin in Young Children Study Group and the Cystic Fibrosis Foundation Therapeutics Development Network. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr 2009;154:183-8.
10. Chmiel JF, Berger M, Konstan MW. The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol 2002;23:5-27.
11. Armstrong DS, Hook SM, Jamsen KM, et al. Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr Pulmonol 2005;40:500-10.
12. Douglas TA, Brennan S, Gard S, et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur Respir J 2009;33:305-11.
13. Rosenfeld M, Emerson J, Accurso F, et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999;28:321-8.
14. Kosorok MR, Zeng L, West SEH, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001;32:277-87. (Pubitemid 32938876)
15. Nixon GM, Armstrong DS, Carzino R, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001;138:699-704.
16. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91-100.
17. Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005;293:581-8.
18. Courtney JM, Bradley J, Mccaughan J, et al. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol 2007;42:525-32.
19. Johansen HK, Gøtzsche PC. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev 2008;(4):CD001399.
20. Döring G, Høiby N; For the Consensus Study Group. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004;3:67-91.
21. Heinzl B, Eber E, Oberwaldner B, et al. Effects of inhaled gentamicin prophylaxis on acquisition of Pseudomonas aeruginosa in children with cystic fibrosis: a pilot study. Pediatr Pulmonol 2002;33:32-7.
22. Lebecque P, Leal T, Zylberberg K, et al. Towards zero prevalence of chronic Pseudomonas aeruginosa infection in children with cystic fibrosis. J Cyst Fibros 2006;5:237-44.
23. Tramper-Stranders GA, Wolfs TFW, van Haren Noman S, et al. Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Thorax 2010;65:897-902.
24. Valerius N, Koch C, Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991;338:725-6.
25. Armstrong DS, Grimwood K, Carlin JB, et al. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis. Pediatr Pulmonol 1996;21:267-75.
26. Gutierrez JP, Grimwood K, Armstrong DS, et al. Interlobar differences in bronchoalveolar lavage fluid from children with cystic fibrosis. Eur Respir J 2001;17:281-6.
27. Ratjen F, Walter H, Haug M, et al. Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients. Pediatr Pulmonol 2007;42:249-55.
28. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2009;(4):CD004197.
29. Jones AM. Eradication therapy for early Pseudomonas aeruginosa infection in CF: many questions still unanswered. Eur Respir J 2005;26:373-5.
30. Eber E, Thalhammer GH, Zach MS. Eradication of Pseudomonas aeruginosa in cystic fibrosis. Eur Respir J 2006;27:438-9.
31. Gibson RL, Emerson J, Mayer-Hamblett N, et al; For the Inhaled Tobramycin in Young Children Study Group and the Cystic Fibrosis Foundation Therapeutics Development Network. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol 2007;42:610-23.
32. Ratjen F, Munck A, Kho P, et al; For the ELITE Study Group. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010;65:286-91.
33. Que C, Cullinan P, Geddes D. Improving rate of decline of FEV1 in young adults with cystic fibrosis. Thorax 2006;61:155-7.
34. Konstan MW, Morgan WJ, Butler SM, et al; For the Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007;151:134-9.
35. Daviskas E, Anderson SD, Brannan JD, et al. Inhalation of dry-powder mannitol increases mucociliary clearance. Eur Respir J 1997;10:2449-54.
36. Jaques A, Daviskas E, Turton JA, et al. Inhaled mannitol improves lung function in cystic fibrosis. Chest 2008;133:1388-96.
37. Daviskas E, Anderson SD, Jaques A, et al. Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis. Chest 2010;137:861-8.
38. Minasian C, Wallis C, Metcalfe C, et al. Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trial. Thorax 2010;65:51-6.
39. Frederikson B, Pressler T, Hansen A, et al. Effect of aerosolized rhDNase (Pulmozyme®) on pulmonary colonization in patients with cystic fibrosis. Acta Pædiatr 2006;95:1070-4.
40. Ring E, Eber E, Erwa W, et al. Urinary N-acetyl-β-D-glucosaminidase activity in patients with cystic fibrosis on long term gentamicin inhalation. Arch Dis Child 1998;78:540-3.
41. Bockenhauer D, Hug MJ, Kleta R. Cystic fibrosis, aminoglycoside treatment and acute renal failure: the not so gentle micin. Pediatr Nephrol 2009;24:925-8.
42. Emerson J, McNamara S, Buccat AM, et al. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr Pulmonol 2010;45:363-70.
43. Treggiari MM, Rosenfeld M, Mayer-Hamblett N, et al; EPIC Study Group. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study. Contemp Clin Trials 2009;30:256-68.